Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Conditions
Interventions
Vedolizumab 300 mg IV
Placebo IV
+2 more
Locations
174
United States
Arkansas Primary Care Clinic, PA
Little Rock, Arkansas, United States
Rocky Mountain Clinical Research, LLC
Wheat Ridge, Colorado, United States
Middlesex Gastroenterology Associates
Middletown, Connecticut, United States
Nature Coast Clinical Research, LLC
Inverness, Florida, United States
Florida Center for Gastroenterology
Largo, Florida, United States
L & L Research Choices, Inc.
Miami, Florida, United States
Start Date
December 18, 2015
Primary Completion Date
May 30, 2018
Completion Date
August 21, 2018
Last Updated
May 25, 2022
NCT06294925
NCT05076175
NCT06359808
NCT06651281
NCT04121806
NCT06065228
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions